Two Sigma Securities’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.66M Buy
+8,606
New +$927K 0.13% 168
2023
Q4
– Sell
-8,326
Closed -$700K – 3385
2023
Q3
$860K Sell
8,326
-3,575
-30% -$399K 0.01% 1151
2023
Q2
$1.45M Sell
11,901
-38,525
-76% -$5.14M 0.02% 763
2023
Q1
$7.74M Buy
50,426
+9,813
+24% +$1.62M 0.16% 144
2022
Q4
$7.29M Sell
40,613
-6,428
-14% -$1.05M 0.22% 88
2022
Q3
$5.56M Buy
47,041
+22,343
+90% +$3.39M 0.17% 129
2022
Q2
$3.53M Sell
24,698
-10,495
-30% -$1.5M 0.13% 174
2022
Q1
$6.06M Buy
35,193
+32,887
+1,426% +$5.54M 0.21% 96
2021
Q4
$586K Sell
2,306
-675
-23% -$197K 0.03% 455
2021
Q3
$1.15M Sell
2,981
-3,427
-53% -$1.26M 0.03% 445
2021
Q2
$1.51M Buy
6,408
+3,813
+147% +$681K 0.05% 306
2021
Q1
$340K Sell
2,595
-407
-14% -$59K 0.02% 392
2020
Q4
$314K Buy
+3,002
New +$304K 0.01% 1004

Other funds holding MRNA

Two Sigma Securities's MRNA Position: Q3 2026 in Review

Two Sigma Securities opened a new position in Moderna (MRNA) in Q3 2026: 8,606 shares worth $1.66M. The stake represents 0.13% of the portfolio and ranks #168 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in MRNA as recently as Q3 2023.

Two Sigma Securities first reported a position in MRNA in Q4 2020 and has held it in 13 quarters since. The position peaked at $7.74M in Q1 2023. 1,053 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Two Sigma Securities held 8,606 shares of Moderna worth $1.66M as of Q3 2026.
  • Moderna was a new Two Sigma Securities position in Q3 2026.
  • Moderna made up 0.13% of Two Sigma Securities's portfolio in Q3 2026, its #168 holding.
  • Two Sigma Securities first reported a position in Moderna in Q4 2020 and has held it in 13 quarters since.
  • Two Sigma Securities's Moderna position peaked at $7.74M in Q1 2023.
  • 1,053 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Two Sigma Securities's 13F filing for Q3 2026, filed 16 Nov 2026.